TOLERABILITY
Clinical trials for TOLERABILITY explained in plain language.
Never miss a new study
Get alerted when new TOLERABILITY trials appear
Sign up with your email to follow new studies for TOLERABILITY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill shows promise in early trial for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests an experimental oral drug, IPG7236, in adults with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 196 participants will take the pill tw…
Matched conditions: TOLERABILITY
Phase: PHASE1, PHASE2 • Sponsor: Nanjing Immunophage Biotech Co., Ltd • Aim: Disease control
Last updated May 26, 2026 04:20 UTC
-
New drug HY07121 aims to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis study tests a new drug, HY07121, in 258 adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe, tolerable, and can shrink tumors. Participants receive the drug by infusion, and the study will monitor side effe…
Matched conditions: TOLERABILITY
Phase: PHASE1, PHASE2 • Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd • Aim: Disease control
Last updated May 26, 2026 04:20 UTC
-
New pill targets hard-to-treat KRAS cancers in early human trial
Disease control Recruiting nowThis study tests an experimental drug called HYP-2090PTSA in people with advanced solid tumors that have a KRAS mutation. The goal is to find a safe dose and see if the drug can shrink tumors. About 257 adults will take part in two phases: first to check safety, then to measure e…
Matched conditions: TOLERABILITY
Phase: PHASE1, PHASE2 • Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd • Aim: Disease control
Last updated May 26, 2026 04:15 UTC
-
New growth hormone injection enters first human safety tests
Disease control Recruiting nowThis early-stage study tests whether a new medicine called GenSci134 is safe and tolerable for people. It involves healthy adults and patients with adult growth hormone deficiency, a condition where the body doesn't make enough growth hormone. Participants receive either the stud…
Matched conditions: TOLERABILITY
Phase: PHASE1 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 18, 2026 12:07 UTC
-
New injection aims to tame overactive thyroid
Disease control Recruiting nowThis early-stage study tests a single injection of a new drug called GenSci098 in 24 adults with Graves' disease, a condition where the thyroid is overactive. The main goal is to see if the drug is safe and what side effects it might cause. Participants must have stopped other th…
Matched conditions: TOLERABILITY
Phase: PHASE1 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New injection for thyroid eye disease enters first human safety study
Disease control Recruiting nowThis early-stage study tests the safety of a new drug called GenSci098 in 76 adults with active thyroid eye disease (TED). Participants receive one or more injections under the skin, and researchers monitor for side effects and how the drug moves through the body. The goal is to …
Matched conditions: TOLERABILITY
Phase: PHASE1 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 08, 2026 12:00 UTC
-
New inhaled drug RCS-21 put to the test in healthy volunteers
Knowledge-focused Recruiting nowThis early-stage study tests whether a single inhaled dose of RCS-21 is safe and tolerable in 24 healthy adults aged 18 to 64. Participants receive one dose and are closely monitored for side effects. The study does not aim to treat any disease, but to gather important safety and…
Matched conditions: TOLERABILITY
Phase: PHASE1 • Sponsor: RNATICS GmbH • Aim: Knowledge-focused
Last updated May 26, 2026 04:17 UTC